Renal impairment, including with ESRD on dialysis Deep Vein Thrombosis: No dose adjustment recommended; not studied in ESRD on dialysis or patients with a CrCl <15 mL/min; dosing recommendations based on pharmacokinetic and pharmacodynamic (anti-FXa activity) data in study subjects with ESRD maintai...
8.6 Renal Impairment Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation The recommended dose is 2.5 mg twice daily in patients with at least two of the following characteristics [see Dosage and Administration (2.1)]: • age greater than or equal...
The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively. Bleedin...
The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively. Bleedin...
Renal impairment (dose ↓ may be required); Moderate hepatic impairment (↑ risk of bleeding); Rep: Women of reproductive potential; OB: Use during pregnancy only if potential maternal benefit justifies potential fetal risk;Pedi: Safety and effectiveness not established in children. Adverse Reactions...
Renal and urinary disorders:hematuria (including respective laboratory parameters) Injury, poisoning, and procedural complications:wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage Less common adverse reactions in ELIQUIS-treated patients undergoing hip or knee re...
Renal and urinary disorders:hematuria (including respective laboratory parameters) Injury, poisoning, and procedural complications:wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage Less common adverse reactions in ELIQUIS-treated patients undergoing hip or knee re...
Renal and urinary disorders:hematuria (including respective laboratory parameters) Injury, poisoning, and procedural complications:wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage Less common adverse reactions in ELIQUIS-treated patients undergoing hip or knee re...
Renal and urinary disorders:hematuria (including respective laboratory parameters) Injury, poisoning, and procedural complications:wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage Less common adverse reactions in ELIQUIS-treated patients undergoing hip or knee re...
Renal and urinary disorders:hematuria (including respective laboratory parameters) Injury, poisoning, and procedural complications:wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage Less common adverse reactions in ELIQUIS-treated patients undergoing hip or knee re...